ARGX vs. TECH: argenx vs. Bio-Techne Stock Comparison

November 11, 2026

How do argenx (ARGX) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Bio-Techne (TECH) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Bio-Techne (TECH)
Profile Item	ARGX	TECH
Name	argenx SE American Depositary Receipt	Bio-Techne Corp.
Country/Region	Netherlands	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	58.31 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	May 18, 2017	February 9, 1989
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

ARGX

TECH

GSPC

argenx (ARGX) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for argenx (ARGX) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for argenx (ARGX) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
Total Return (1Y)	11.91%	27.56%
Total Return (3Y, Annualized)	25.68%	9.11%
Total Return (5Y, Annualized)	24.22%	-9.91%

Risk Profile

Drawdown History

ARGX

TECH

GSPC

argenx (ARGX) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for argenx (ARGX) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
Volatility (1Y, Annualized)	37.87%	43.08%
Beta (5Y)	0.45	1.26
Max Drawdown (5Y)	-38.20%	-65.87%
Avg. Volume (3M)	359.84K	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

ARGX and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
Sharpe Ratio (1Y)	0.20	0.54
Sortino Ratio (1Y)	0.31	0.82

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Bio-Techne (TECH) earns 8.33% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ARGX: --

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

argenx (ARGX) vs. Bio-Techne (TECH): ARGX does not report ROE, so it has no value marker; TECH is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

argenx (ARGX) at 31.73% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX: 31.73%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

argenx (ARGX) at 36.27% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max: 83.12%
ARGX: 36.27%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
ROE (TTM)	--	8.33%
ROA (TTM)	--	6.38%
Net Margin (TTM)	31.73%	14.00%
Operating Margin (TTM)	36.27%	12.21%
Gross Margin (TTM)	59.84%	66.23%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Bio-Techne (TECH) at -0.38% is closer to the peer norm — faster top-line expansion for ARGX.

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while argenx (ARGX) at 53.13% is closer to the peer norm — faster per-share earnings growth for TECH.

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
Revenue Growth (YoY)	89.64%	-0.38%
Revenue Growth (3Y CAGR)	116.25%	2.25%
EPS Growth (YoY)	53.13%	152.17%
EPS Growth (3Y CAGR)	--	-12.97%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Bio-Techne (TECH) shows current ratio of 2.28 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10
ARGX: --

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

argenx (ARGX) vs. Bio-Techne (TECH): ARGX does not report current ratio, so it has no value marker; TECH is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Bio-Techne (TECH) at 0.13 runs a more typical debt-to-equity mix.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
ARGX: 0.01
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
Current Ratio (MRQ)	--	2.28
Debt / Equity (MRQ)	0.01	0.13
Net Debt / EBITDA	-2.70	-0.20

Dividends

Dividend Yield (TTM)

argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

argenx (ARGX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
Dividend Yield (TTM)	0.00%	0.44%
Dividend Payout Ratio (TTM)	0.00%	27.59%

Valuation

P/E Ratio (TTM)

argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max: 85.34
Q3: 43.46
ARGX: 32.12
Median: 26.69
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both argenx (ARGX) at 9.86 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max: 58.18
Q3: 25.77
ARGX: 9.86
Median: 7.30
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Techne (TECH) at 5.28 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX: 172.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

argenx (ARGX) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Bio-Techne (TECH)
Metric	ARGX	TECH
P/E Ratio (TTM)	32.12	62.74
P/S Ratio (TTM)	9.86	9.31
P/B Ratio (MRQ)	172.23	5.28
Free Cash Flow Yield (TTM)	--	2.39%